Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370287 · ClinicalTrials.gov registry record · NA
Adaptive Optics Retinal Imaging
A NA study of Glaucoma, Primary Open Angle, sponsored by Food and Drug Administration (FDA).
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05370287 is a NA study of Glaucoma, Primary Open Angle that is actively recruiting participants, run by Food and Drug Administration (FDA). The registered enrollment target is 80 participants, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05370287, a NA study of Glaucoma, Primary Open Angle, is actively recruiting participants, sponsored by Food and Drug Administration (FDA).
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
Conditions Studied
Interventions
- OTHER oxygen inhalation
- DEVICE Adaptive optics imaging
Study Locations (1)
Maryland
- Food and Drug Administration - Silver Spring
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-01-22 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05370287
The ClinicalTrials.gov registry entry for NCT05370287 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (45% higher). The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 2 interventions - of which oxygen inhalation is the first listed.
NCT05370287 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05370287 about?
NCT05370287 is a clinical study titled "Adaptive Optics Retinal Imaging". The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.
What is the current status of trial NCT05370287?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2018-01-22. Estimated completion is 2026-09-30.
What conditions does trial NCT05370287 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT05370287?
The interventions under investigation include: oxygen inhalation (OTHER), Adaptive optics imaging (DEVICE).
Who is sponsoring clinical trial NCT05370287?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370287 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
RECRUITING · NA
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
-
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.